With Novartis’s oral contender looming, Astra talks up the importance of terminal complement inhibition.
Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.
A pivotal lung cancer hit in an outdated setting means the company might struggle with adoption.
The search is on for signals in front-line use, where Daiichi Sankyo and Astrazeneca have already bet big with the Trop2-targeted project.
China’s Dizal, an unexpected targeted therapy star of Asco 2021, is back with even more impressive data.
Strong data prompt talk of a tumour-agnostic approval, but regulators could prove reluctant in the broad Her2 setting.
Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.